Thoracal Radiotherapy and Tarceva

Sponsor
Oslo University Hospital
Study ID
NCT02714530
Phase
PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Tarceva daily during radiotherapy course
  • Radiation — RADIATION
    Radiotherapy

Study Details

The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.

Key Dates

First listed
Mar 21, 2016
Start date
Apr 1, 2014
Status verified
Mar 2021
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020

Study Design

Enrollment
118 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Radiotherapy combined with erlotinib
    Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
  • Active Comparator: Radiotherapy alone
    Radiotherapy 3 Gy x 10 alone

Primary Outcome Measure

Number of patients with progression in radiation field among patients treated with erlotinib combined with radiotherapy compared to radiotherapy alone [ Time Frame: 1 year ]

Related Studies